554 656
Funding/Support and role of the sponsor:
Roland Seiler: salary funded by
the Swiss National Foundation. GenomeDx funded gene expression
analysis. Peter C. Black: AUA Foundation/Astellas Rising Stars in urology
award. Bas W.G. van Rhijn: The EAU—European Urological Scholarship
Programme. Michiel S. van der Heijden: Veni grant, Netherlands
Organisation for Scientific Research. The sponsors played a role in the
design and conduct of the study, and in collection, management,
analysis, and interpretation of the data.
Acknowledgments:
We thank the Core Facility for Molecular Pathology &
Bio-banking of the Netherlands Cancer Institute;1;—Antoni van Leeu-
wenhoek for their assistance.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at
http://dx.doi.org/10.1016/j. eururo.2017.03.030 .References
[1]
Bajorin DF, Herr HW. Kuhn’s paradigms: are those closest to treat- ing bladder cancer the last to appreciate the paradigm shift? J Clin Oncol 2011;29:2135–7.[2]
Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemo- therapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859–66.[3]
International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party, European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for mus- cle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011;29:2171–7.[4]
Zargar H, Espiritu PN, Fairey AS, et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2015;67:241–9.[5]
Groenendijk FH, de Jong J, Fransen van de Putte EE, et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol 2016;69:384–8.[6]
Liu D, Plimack ER, Hoffman-Censits J, et al. Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma. JAMA Oncol 2016;2:1094–6.[7]
Plimack ER, Dunbrack RL, Brennan TA, et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemother- apy in muscle-invasive bladder cancer. Eur Urol 2015;68:959–67.[8]
Van Allen EM, Mouw KW, Kim P, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 2014;4:1140–53.[9]
Biton A, Bernard-Pierrot I, Lou Y, et al. Independent component analysis uncovers the landscape of the bladder tumor transcrip- tome and reveals insights into luminal and basal subtypes. Cell Rep 2014;9:1235–45.[10]
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507: 315–22.
[11]
Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014;25: 152–65.
[12]
Damrauer JS, Hoadley KA, Chism DD, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 2014;111:3110–5.[13]
Sjodahl G, Lauss M, Lovgren K, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res 2012;18:3377–86.
[14]
Volkmer JP, Sahoo D, Chin RK, et al. Three differentiation states risk- stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci U S A 2012;109:2078–83.
[15]
Kardos J, Chai S, Mose LE, et al. Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. JCI Insight 2016;1:e85902.[16]
Erho N, Crisan A, Vergara IA, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One 2013;8:e66855.[17]
Piccolo SR, Sun Y, Campbell JD, Lenburg ME, Bild AH, Johnson WE. A single-sample microarray normalization method to facilitate per- sonalized-medicine workflows. Genomics 2012;100:337–44.
[18]
Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909–20.[19]
Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18:312–22.
[20]
von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012;30:1796–804.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 5 4 4 – 5 5 4
554